|
gptkbp:instanceOf
|
antidepressant
brand name drug
|
|
gptkbp:activeIngredient
|
venlafaxine hydrochloride
|
|
gptkbp:approvalYear
|
1997
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:associatedWith
|
gptkb:Pristiq
gptkb:Cymbalta
gptkb:Desvenlafaxine
gptkb:Duloxetine
|
|
gptkbp:ATCCode
|
gptkb:N06AX16
|
|
gptkbp:contraindication
|
concurrent MAOI use
|
|
gptkbp:drugClass
|
norepinephrine reuptake inhibitor
|
|
gptkbp:eliminatedIn
|
renal
|
|
gptkbp:form
|
150 mg
225 mg
75 mg
extended-release capsule
37.5 mg
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:halfLife
|
about 5 hours (venlafaxine), 11 hours (O-desmethylvenlafaxine)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Effexor XR
|
|
gptkbp:indication
|
gptkb:generalized_anxiety_disorder
gptkb:panic_disorder
gptkb:social_anxiety_disorder
gptkb:major_depressive_disorder
|
|
gptkbp:legalStatus
|
Rx-only (US)
|
|
gptkbp:manufacturer
|
gptkb:Pfizer
|
|
gptkbp:mechanismOfAction
|
inhibits reuptake of serotonin and norepinephrine
weak inhibition of dopamine reuptake
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:overdoseSymptoms
|
gptkb:arrhythmia
vomiting
seizures
tachycardia
|
|
gptkbp:patentExpired
|
yes
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:riskFactor
|
gptkb:discontinuation_syndrome
gptkb:serotonin_syndrome
hypertension
suicidal thoughts (in young adults and children)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
dizziness
sweating
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:bfsParent
|
gptkb:venlafaxine
gptkb:Venlafaxine
|
|
gptkbp:bfsLayer
|
7
|